^3^H

:   tritiated

5‐HT

:   5‐hydroxytryptamine (serotonin)

5‐HT~1A~

:   serotonin 1A receptor

5‐HT₂

:   serotonin 2 receptor

5‐HT~2A~

:   serotonin 2A receptor

5‐HTT

:   serotonin transporter

ACC

:   anterior cingulate cortex

ADHD

:   attention‐deficit/hyperactivity disorder

ADI‐R

:   autism diagnostic interview‐revised

ASD

:   autism spectrum disorders

*B*~max~

:   receptor density

CDC

:   Centers for Disease Control and Prevention

FG

:   fusiform gyrus

fMRI

:   functional magnetic resonance imaging

*K*~D~

:   equilibrium dissociation constant

nCi

:   nanocuries

PCC

:   posterior cingulate cortex

PET

:   positron emission tomography

PMI

:   postmortem interval

SLC6A4

:   serotonin transporter gene

SPECT

:   single photon emission computed tomography

SSRIs

:   selective serotonin reuptake inhibitors

Peripheral hyperserotonemia was the earliest demonstrated neurochemical change in individuals with autism spectrum disorders (ASD) (Schain and Freedman [1961](#jnc14832-bib-0062){ref-type="ref"}) and has since become the best replicated biomarker, as recent meta‐analyses conclude that hyperserotonemia is present in 25--45% of the autism population (Gabriele *et al.* [2014](#jnc14832-bib-0021){ref-type="ref"}; Chen *et al.* [2017](#jnc14832-bib-0009){ref-type="ref"}; Eissa *et al.* [2018](#jnc14832-bib-0019){ref-type="ref"}). Furthermore, whole blood maternal serotonin levels during pregnancy are associated with altered cognitive abilities and core neurodevelopmental outcomes in offspring with ASD (Montgomery *et al.* [2018](#jnc14832-bib-0043){ref-type="ref"}).

In the last decade, attention also has been directed toward the study of central serotonin levels as serotonin (5‐HT) plays important roles in neurogenesis, cell migration, synaptogenesis, plasticity, 5‐HT transporter (5‐HTT) function, and signalling during brain development and maturation, as well as a variety of other neural processes (for review see: Garbarino *et al.* [2018](#jnc14832-bib-0022){ref-type="ref"}). The usage of drugs targeting 5‐HTT has been increased in an effort to treat symptoms of depression and/or other core symptoms in a variety of neuropsychiatric disorders. In a Centers for Disease Control and Prevention report, between 2011 and 2014, 12.7% of persons over 12 years of age had used antidepressant medications in the previous month, 68% took these medications for 2 years or more, while 25% took them for 10 years or more (Pratt *et al.* [2017](#jnc14832-bib-0060){ref-type="ref"}).

Selective serotonin reuptake inhibitors (SSRIs) have been effective in treating patients with major depressive, anxiety and obsessive compulsive disorders and have been widely prescribed to individuals with autism for the treatment of repetitive behaviors (King and Bostic [2006](#jnc14832-bib-0032){ref-type="ref"}), as 21--32% of chlidren with ASD are prescribed one or more antidepressant medications (Langworthy‐Lam *et al.* [2002](#jnc14832-bib-0037){ref-type="ref"}; Aman *et al.* [2003](#jnc14832-bib-0001){ref-type="ref"}; Oswald and Sonenklar [2007](#jnc14832-bib-0057){ref-type="ref"}). Pharmacotherapeutic treatment for individuals with autism has been largely off‐label (Oswald and Sonenklar [2007](#jnc14832-bib-0057){ref-type="ref"}) and often not directed toward core symptoms of the condition (Gibbs [2010](#jnc14832-bib-0023){ref-type="ref"}). In a seminal clinical trial by King *et al.*([2009](#jnc14832-bib-0033){ref-type="ref"}), citalopram hydrobromide, an SSRI that primarily targets 5‐HTT, was administered to 149 children with ASD aged 5--17 years for 12 weeks from six academic institutions. Instead of seeing significant improvement in symptoms and/or behavior, the citalopram hydrombromide group experienced adverse effects of the drug, including increased energy level and hyperactivity, insomnia, reduced concentration, impulsiveness, and stereotyped behaviors. Recently, a case report in which four children 6--12 years old with ASD were given low doses of the SSRI fluoxetine found improvement in attention‐deficit/hyperactivity disorder‐like symptoms, irritability and/or self‐injurious behavior (Lucchelli and Bertschy [2018](#jnc14832-bib-0040){ref-type="ref"}). Previously, Hollander *et al.*([2012](#jnc14832-bib-0026){ref-type="ref"}) found improvement in repetitive behaviors in adult ASD subjects who were administered fluoxetine while McDougle *et al.*([1996](#jnc14832-bib-0042){ref-type="ref"}), in a clinical trial using the SSRI fluvoxamine, reported improvement in aggressive behavior in adult ASD patients. However, a Cochrane Review including 320 participants concluded there is no evidence for SSRIs as effective treatments for autism in children, but there is limited evidence for effectiveness in adults (Williams *et al.* [2013](#jnc14832-bib-0076){ref-type="ref"}). These and other studies suggest that there are differential effects depending on the specific dose‐dependent SSRI administered, with citalopram being the least effective in ameliorating or modulating autism‐related behaviors.

Nevertheless, there is substantial evidence that 5‐HT systems are altered in ASD in both humans and in animal models (for review see: Muller *et al.* [2016](#jnc14832-bib-0044){ref-type="ref"}). Many individuals with ASD and some of their family members have increased blood 5‐HT levels (Schain and Freedman [1961](#jnc14832-bib-0062){ref-type="ref"}; Cook and Leventhal [1996](#jnc14832-bib-0013){ref-type="ref"}; Lam *et al.* [2006](#jnc14832-bib-0036){ref-type="ref"}; Gabriele *et al.* [2014](#jnc14832-bib-0021){ref-type="ref"}) and genetic variation in 5‐HTT in some individuals with autism has been reported (Yonan *et al.* [2003](#jnc14832-bib-0077){ref-type="ref"}; Devlin *et al.* [2005](#jnc14832-bib-0018){ref-type="ref"}; Sutcliffe *et al.* [2005](#jnc14832-bib-0069){ref-type="ref"}; Kistner‐Griffin *et al.* [2011](#jnc14832-bib-0034){ref-type="ref"}). Positron emission tomography (PET) imaging studies have demonstrated abnormal 5‐HT synthesis in brain regions in autism (Chugani *et al.* [1997](#jnc14832-bib-0011){ref-type="ref"}; Chugani *et al.* [2001](#jnc14832-bib-0012){ref-type="ref"}; Chandana *et al.* [2005](#jnc14832-bib-0008){ref-type="ref"}) and a polymorphism in the gene for the serotonin transporter (SLC6A4) has been associated with increased cerebral cortex grey matter volume in children with ASD (Wassink *et al.* [2007](#jnc14832-bib-0073){ref-type="ref"}).

These early clinical, imaging, and genetic studies demonstrated 5‐HT alterations in the autism brain, supported the use of 5‐HT as a biomarker and suggested the potential for novel biomarkers to be found in different 5‐HT receptor subtypes, which led to several imaging studies that focused primarily on high‐functioning individuals with autism. A PET imaging study of a high‐functioning autism cohort (*n* = 20, 18--26 years of age) revealed decreased 5‐HTT binding in the anterior cingulate cortex (ACC), posterior cingulate cortex (PCC) and thalamus, which was associated with behavioral changes, including impairment of social cognition and repetitive/obsessive actions and interests (Nakamura *et al.* [2010](#jnc14832-bib-0050){ref-type="ref"}). Makkoen *et al.*([2008](#jnc14832-bib-0041){ref-type="ref"}) used single photon emission computed tomography on a small group of high‐functioning children and adolescents and found decreased 5‐HTT binding in the medial frontal lobe, especially in the adolescent cohort, whereas 5‐HTT binding in the midbrain and temporal lobe was normal. In another imaging study, Murphy *et al.*([2006](#jnc14832-bib-0047){ref-type="ref"}) utilized the ligand ^123^I‐5‐I‐R91150 that shows selectivity for 5‐HT~2~ receptors and reported significant binding decreases associated with social communication deficits. Additionally, parents of children with ASD have been reported to have significantly decreased cortical 5‐HT~2~ receptor binding, with a negative correlation to their platelet 5‐HT levels using PET imaging (Goldberg *et al.* [2009](#jnc14832-bib-0024){ref-type="ref"}).

In contrast to high‐functioning autism, there is a paucity of investigations that include idiopathic autism cases, making it difficult to generalize potential pharmacotherapies toward affected receptors across the autism spectrum. In one of the few studies of idiopathic autism, Azmitia *et al.*([2011](#jnc14832-bib-0003){ref-type="ref"}) utilized immunocytochemistry in postmortem autism and neurotypical control cases 2--29 years to label serotonergic fibers in the forebrain cortical white matter and their projections into the temporal cortex. These investigators identified an increased number of 5‐HT axons in the autism group, leading to the conclusion that physicians should use caution in prescribing SSRIs to children. These authors also postulated that the increased number of 5‐HT axons could have profound effects on 5‐HT receptor subtypes, including the presynaptic 5‐HT~1A~ receptors and the abundant 5‐HT~2A~ receptors, thus affecting synaptogenesis and ultimately function.

However, there are very few studies analyzing 5‐HT receptor differences within the postmortem brain of individuals with autism. Our initial findings based on single concentration ligand binding studies in young adults with ASD provided strong evidence for alterations in brain 5‐HT systems in autism due to the high sensitivity of autoradiography methods, with reductions in density of 5‐HT~1A~ and 5‐HT~2A~ receptors in the PCC and fusiform gyrus (FG), but no change in binding to the transporter 5‐HTT (Oblak *et al.* [2013](#jnc14832-bib-0056){ref-type="ref"}). This suggested that pharmacotherapies targeted toward affected 5‐HT receptor subtypes identified within different individuals may lead to improved therapeutic outcomes.

We thus aimed to expand on our initial single concentration ligand study (Oblak *et al.* [2013](#jnc14832-bib-0056){ref-type="ref"}) by increasing the cohort size and comparing multiple concentrations of three 5‐HT ligands in three cortical regions within ASD cases that span a range of severity in diagnosis. In addition to the PCC and FG, we included the ACC, which had not been evaluated in the previous study. *Here, we perform multiple concentration saturation binding assays in a cohort of human postmortem brain tissue from individuals with idiopathic autism as compared to age‐matched neurotypical control brains*. This design allows for determination between a change in receptor density (*B* ~max~) and/or a change in ligand affinity (*K* ~D~), which might arise due to post­translational modification of receptors, receptor oligomerization, or association of receptors with modulatory proteins (Nichols and Nichols [2008](#jnc14832-bib-0051){ref-type="ref"}). 5‐HT~1A~ and 5‐HT~2~ receptors, as well as the transporter 5‐HTT, were quantified in both superficial and deep laminar layers in the ACC, PCC and FG. This larger cohort allowed for separation of cases based on age (adults \> 16 years and children/adolescents ≤ 16 years) to mimic clinical trials that found differential age‐related results with SSRI use.

In one of the largest postmortem autism studies to date, our results indicate alterations in the 5‐HT system within the adult ACC. The ACC is one of the most consistently reported abnormal cortical regions in behavioral, imaging, and pathological studies in autism (Bauman and Kemper [1985](#jnc14832-bib-0006){ref-type="ref"}; Bailey *et al.* [1998](#jnc14832-bib-0004){ref-type="ref"}; Simms *et al.* [2009](#jnc14832-bib-0067){ref-type="ref"}; Forde *et al.* [2018](#jnc14832-bib-0020){ref-type="ref"}) and plays fundamental roles in cognitive processes such as motivation, decision making, learning, cost‐benefit calculation, as well as conflict and error monitoring (Shackman *et al.* [2011](#jnc14832-bib-0065){ref-type="ref"}; Holroyd and Yeung [2012](#jnc14832-bib-0028){ref-type="ref"}; Rushworth *et al.* [2012](#jnc14832-bib-0061){ref-type="ref"}; Shenhav *et al.* [2013](#jnc14832-bib-0066){ref-type="ref"}; Ullsperger *et al.* [2014](#jnc14832-bib-0070){ref-type="ref"}; Holroyd and McClure [2015](#jnc14832-bib-0027){ref-type="ref"}; Verguts *et al.* [2015](#jnc14832-bib-0072){ref-type="ref"}; Laubach *et al.* [2015](#jnc14832-bib-0038){ref-type="ref"}; Kolling *et al.* [2016](#jnc14832-bib-0035){ref-type="ref"}; Apps *et al.* [2016](#jnc14832-bib-0002){ref-type="ref"}). An emerging role for the ACC in social cognition, particularly tracking the motivation of others (for review see: Apps *et al.* [2016](#jnc14832-bib-0002){ref-type="ref"}), may be especially relevant in the context of ASD as it is thought that autistic individuals lack social motivation (Mundy and Neal [2000](#jnc14832-bib-0045){ref-type="ref"}; Dawson *et al.* [2005](#jnc14832-bib-0016){ref-type="ref"}; Schultz [2005](#jnc14832-bib-0063){ref-type="ref"}; Chevallier *et al.* [2012](#jnc14832-bib-0010){ref-type="ref"}). Therefore, the ACC may represent a vulnerable area in ASD, which has been shown to have relevance to ASD specific behaviors.

Materials and methods {#jnc14832-sec-0002}
=====================

Postmortem tissue {#jnc14832-sec-0003}
-----------------

Human postmortem brain tissue was obtained from the University of Maryland Brain and Tissue Bank, a brain and tissue repository of the NIH Neurobiobank, and from the Harvard Brain and Tissue Resource Center of the Autism Tissue Program, which is now Autism BrainNet. Case demographics are provided in Table [1](#jnc14832-tbl-0001){ref-type="table"}. Fresh frozen tissue blocks from the left hemisphere of three cortical regions including the ACC (*n* = 19 control, *n* = 18 autism), PCC (*n* = 18 control, *n* = 19 autism), and FG (*n* = 18 control, *n* = 14 autism) were sectioned coronally at 20 µm on a cryostat and kept frozen at −80˚C. There were no statistically significant differences in total case ages (*p* = 0.14) or postmortem interval (*p* = 0.23) between autism and control cases using a Welch's *t*‐test. All autism cases had confirmed diagnoses through the autism diagnostic interview‐revised (ADI‐R) scores and/or received a clinical diagnosis of autism from a licensed psychiatrist. Ten autism cases had at least one seizure reported and seven had reported medications (Table [1](#jnc14832-tbl-0001){ref-type="table"}).

###### 

Postmortem brain donor case demographics.

  Cases                          Diagnosis   Age   PMI   Gender   Ethnicity            Cause of Death                                    Brain Bank‐ Seizure
  ------------------------------ ----------- ----- ----- -------- -------------------- ------------------------------------------------- ---------------------
  **Adults \>16**                                                                                                                        
  602                            Control     27    15    M        Caucasian            Accident, multiple injuries                       UMBTB
  1026                           Control     28    6     M        Caucasian            Congenital Heart Disease                          ATP
  1365                           Control     28    17    M        Caucasian            Multiple injuries                                 ATP
  4103                           Control     43    23    M        Caucasian            Heart attack/disease                              ATP
  4104                           Control     24    5     M        African American     Gun shot to the chest                             ATP
  4267                           Control     26    20    M        African American     Accident                                          ATP
  4268                           Control     30    22    M        African American     Cardiomyopathy (heart attack/disease)             ATP
  4271                           Control     19    21    M        African American     Epiglottis/unknown                                ATP
  4272                           Control     19    17    M        Caucasian            Accident                                          ATP
  4275                           Control     20    16    M        Caucasian            Accident                                          ATP
  4345                           Control     27    19    F        Caucasian            Respiratory failure                               UMBTB
  4364                           Control     27    27    M        Unknown              Motor vehicle accident                            ATP
  4599                           Control     23    18    M        African American     Cardiac arrthymia/anomalous coronary artery       UMBTB
  4605                           Control     29    17    M        African American     Commotio cordis                                   ATP
  4916                           Control     19    5     M        Caucasian            Accident, drowning                                ATP
  5321                           Control     19    12    F        Unknown              Accident                                          ATP
  5813                           Control     20    24    M        African American     Atherosclerotic cardiovascular disease            UMBTB
  5873                           Control     28    23    M        African American     Unknown                                           ATP
  6004                           Control     36    18    F        African American     Unknown                                           ATP
  1078                           Autism      22    14    M        Caucasian            Congenital heart disease                          ATP‐ Yes
  1401                           Autism      21    20    F        Caucasian            Sepsis                                            ATP
  1484                           Autism      19    15    M        English‐white        Burns                                             ATP
  1664                           Autism      20    15    M        Unknown              Drowning                                          ATP‐ Yes
  2825^a^                        Autism      19    9     M        Unknown              Cardiac arrest                                    ATP‐ Yes
  3845                           Autism      30    28    M        English‐white        Cancer                                            ATP
  4099                           Autism      19    3     M        Caucasian            Drowning                                          ATP
  5027                           Autism      37    26    M        African american     Obstruction of bowel due to adhesion              UMBTB‐ Yes
  5574                           Autism      23    14    M        African american     Pneumonia                                         UMBTB
  5754                           Autism      20    29    M        Uknown               Unknown                                           ATP
  5771^b^                        Autism      27    5     F        Caucasian            Undetermined                                      UMBTB‐ Epilepsy
  5864^c^                        Autism      20    63    M        Caucasian            Seizure disorder                                  UMBTB
  6337                           Autism      22    25    M        Caucasian            Aspiration                                        ATP
  **Children/adolescents ≤16**                                                                                                           
  1714                           Control     12    22    M        African American     Cardiac arrthymia                                 UMBTB
  3835                           Control     9     8     F        African American     Unknown                                           UMBTB
  4188                           Control     16    13    M        African American     Gunshot                                           ATP
  4274                           Control     16    15    F        Unknown              Accident                                          ATP
  4337                           Control     8     16    M        African American     Blunt force neck injury                           UMBTB
  4670                           Control     4     17    M        Caucasian            Commotio cordis                                   UMBTB
  5170                           Control     13    20    M        African American     Gunshot wound to chest                            UMBTB
  5242                           Control     15    9     M        Caucasian            Cardiac arrhythmia                                UMBTB
  5334                           Control     12    15    M        Hispanic             Hanging/ suicide                                  UMBTB
  5376                           Control     13    19    M        Caucasian            Hanging/suicide                                   UMBTB
  5387                           Control     12    13    M        Caucasian            Drowning                                          UMBTB
  5391                           Control     8     12    M        Caucasian            Drowning                                          UMBTB
  5408                           Control     6     16    M        African American     Drowning                                          UMBTB
  5558                           Control     5     19    M        Caucasian            Anomalous left coronary artery w/ complications   UMBTB
  1469                           Autism      5     42    M        English‐white        Unknown                                           ATP
  2004                           Autism      10    23    M        Asian                Drowning                                          UMBTB
  2993                           Autism      5     4     M        English‐white        Acute respiratory distress syndrome               ATP‐ Yes
  3871                           Autism      5     25    M        Caucasian‐Hispanic   Drowning                                          UMBTB‐ Yes
  3924                           Autism      16    9     F        Portuguese/Spanish   Epilepsy                                          UMBTB‐ Epilepsy
  4334^d^                        Autism      11    27    M        Hispanic             Acute hemorrhagic tracheobronchitis               UMBTB
  4721                           Autism      8     16    M        African american     Drowning                                          UMBTB
  4849                           Autism      7     20    M        African american     Drowning                                          UMBTB
  4899^e^                        Autism      14    9     M        Caucasian            Drowning                                          UMBTB
  5144                           Autism      7     3     M        Caucasian            Complications of cancer                           UMBTB‐ 1 week
                                                                                                                                         before death
  5302                           Autism      16    20    M        Caucasian            Diabetic ketoacidosis                             UMBTB
  5308                           Autism      4     21    M        Caucasian            Skull fractures                                   UMBTB‐ Disorder
  5565^f^                        Autism      12    22    M        African american     Seizure disorder, complications                   UMBTB
  5841^g^                        Autism      12    15    M        Caucasian            Hanging                                           UMBTB

PMI, postmortem interval.

Known medications:

Tegretol, Phenobarbital, Theodor.

Ranitidine, Hydrocodone, Lamictal, Proferrin, Aranesp, Zonegran, Diovan, Microgestin.

Neurontin, Risperidone, Lorazepam, Oxcarbazepine.

Kepra, Lexapro, Biaxin.

Clonidine, Melatonin, Trileptal, Zoloft.

Kepra.

Daytrana, Vyvanse.

John Wiley & Sons, Ltd

As this reasearch did not involve live human subjects, Institutional Review Board approval and informed consent was not necessary. However, the University of Maryland Brain and Tissue Bank is overseen by Institutional Review Board protocol number HM‐HP‐00042077. This study was not pre‐registered.

Saturation ligand binding assays {#jnc14832-sec-0004}
--------------------------------

Three tritiated \[^3^H\] ligands (Perkin Elmer, Boston, MA, USA) including ketanserin \[NET7910 (2015)\] (specific activity (SA) = 47.3 Ci/mmol), citalopram \[NET1039 (2015)\] (SA = 82.1 Ci/mmol), and 8‐OH‐DPAT \[NET929 (2015)\] (SA = 146 Ci/mmol) were utilized as outlined in Table [2](#jnc14832-tbl-0002){ref-type="table"}. All tissues included in each assay were processed under the same conditions at seven different concentrations that spanned 0.51 to 139nM in order to obtain saturation binding curves for each ligand (Oblak *et al.* [2011](#jnc14832-bib-0054){ref-type="ref"}). Two thawed 20 µm sections from each case were used to quantify total binding at each concentration of ligand and one section from each case was exposed to the ligand as well as 100 µM of a displacer (imipramine hydrochloride AAJ6372306, Fisher Scientific, Waltham, MA, USA (2016); ritanserin 1955, Tocris Biosciences, Bristol, UK (2016) and serotonin hydrochloride 3547, Tocris Biosciences (2016)) to determine non‐specific binding (Table [2](#jnc14832-tbl-0002){ref-type="table"}), which was subtracted from the total binding to yield specific binding of the ligand to the respective receptor subtype. All tissues went through a pre‐incubation in buffer without ligand (5‐HT~2~: 50 mM Tris‐HCl (pH 7.4), 4 mM CaCl2, 0.1% ascorbate; 5‐HTT: 50 mM Tris‐HCl (pH 7.4), 120mM NaCl, 5mM KCl; 5‐HT~1A~: 170 mM Tris‐HCl (pH 7.6), 4 mM CaCl2, 0.01% ascorbate) for 30 min before being exposed to the ligand and were then rinsed three times for 5 min in buffer followed by one dip in distilled water and allowed to air‐dry overnight. Slides were placed in X‐ray cassettes with \[^3^H\]‐sensitive hyperfilm \[Kodak Biomax MR film Z350389; Sigma‐Aldrich, St. Louis, MO, USA (2016)\] and a \[^3^H\] standard \[Tritium standards ART0123; American Radiolabeled Chemicals, St. Louis, MO, USA (2015)\] then exposed for 3--26 weeks. Films were processed in a darkroom by developing for 3 min in developer \[Kodak D19 74200; Electron Microscopy Sciences, Hatfield, PA, USA (2015)\], fixed \[Kodak Rapidfix 74312; Electron Microscopy Sciences (2015)\] for 4 min at 23°Cand washed with a stream of water for at least 1 h and air‐dried.

###### 

Multiple concentration binding conditions for serotonin receptor tritiated ligand binding in the ACC, PCC, and FG

  Receptor   Ligand                *K* ~D~   Concentrations (nM)                       Incubation   Displacer            Exposure (weeks)
  ---------- --------------------- --------- ----------------------------------------- ------------ -------------------- ------------------
  5‐HT2      \[^3^H\] Ketanserin   0.5       0.53, 1.0, 2.8, 9.4, 32.5, 89.6, 116.0    30 min       Imipramine           3--24
  5‐HTT      \[^3^H\] Citalopram   3.0       0.51, 1.4, 3.6, 7.8, 30.6, 89.2, 127.0    1 h          Ritanserin           5--24
  5‐HT~1A~   \[^3^H\] 8‐OH‐DPAT    2.0       0.53, 1.5, 2.9, 10.7, 29.1, 91.0, 138.9   1 h          5‐HT Hydrochloride   4--26

5‐HT, 5‐hydroxytryptamine (serotonin); 5‐HTT, serotonin transporter; ACC, anterior cingulate cortex; FG, fusiform gyrus; PCC, posterior cingulate cortex.

John Wiley & Sons, Ltd

Data analysis {#jnc14832-sec-0005}
-------------

Autoradiographs of the tissue sections exposed to film were digitized with a QICAM digital camera (QImaging, Surrey, BC, Canada) and analyzed using MCID Core 7.1 Elite Image analysis system software (InterFocus Imaging Ltd, UK). Calibration of each film with its own \[^3^H\] standard allowed for comparisons across films by choosing one representative standard curve and normalizing all other standard curves and images to it within the MCID software (Linton, UK). The standard curves allowed for conversion from optical density to nanocuries per milligram (mg).

Binding in the superficial layers (I--IV) and deep layers (V--VI) of each cortical region (Fig. [1](#jnc14832-fig-0001){ref-type="fig"}) was sampled with the ribbon tool running along the length of the observable region of interest then converted to femtomoles per mg of protein based on the specific activity of each ligand. The ACC, a limbic cortical area, lacks layer IV, thus superficial sampling in the ACC includes layers I--III. The experimenter was blinded to the diagnosis of the cases during sampling. After background subtraction, these total binding values were plotted against the concentration of ligand and fitted with non‐linear least squares regression to generate saturation binding curves in GraphPad prism 6 to estimate the number of receptors (*B* ~max~) and binding affinity (*K* ~D~) of each ligand for each case.

![Example pseudo‐colored ligand binding images from the ACC. Red represents higher laminar binding. Cortical layers were separated into superficial and deep as shown in the top right image. The same adult case, one control (case 4599, age 23) and one autism (case 5864, age 20) is given for each ligand at 9nM. \[^3^H\]‐ ketanserin and \[^3^H\]‐citalopram have similar binding distribution in the deep and superficial layers, whereas \[^3^H\]‐8‐OH‐DPAT has higher binding in the superficial layers. Note the lower binding in the autism case for 5‐HT~2~ and 5‐HTT, whereas the 5HT~1A~ has the same level of binding as the control. ACC, anterior cingulate cortex; 5‐HT, 5‐hydroxytryptamine (serotonin).](JNC-151-642-g001){#jnc14832-fig-0001}

Statistical analyses {#jnc14832-sec-0006}
--------------------

Equality of variance was calculated with an *F*‐test, and since many of the autism ligand groups compared to the control groups did not show equality of variance, Welch's *t*‐tests were performed to determine differences in the number of estimated total receptors (*B* ~max~). Since the statistical distribution of fitted *K* ~D~ values is log‐normal (Delean *et al.* [1982](#jnc14832-bib-0017){ref-type="ref"}), averaging, calculation of standard errors, and significance testing were carried out on the negative logarithm of *K* ~D~ (pK~D ~= −log*K* ~D~) (Oblak *et al.* [2009](#jnc14832-bib-0052){ref-type="ref"}). Student's *t*‐tests were conducted to compare binding affinity for each ligand in each brain region (Table [3](#jnc14832-tbl-0003){ref-type="table"}). An assessment of normality was conducted using the Shapiro--Wilk test and both control and autism *B* ~max~ and *K* ~D~ values followed a normal distribution. Regression analyses were carried out in Microsoft Excel (2013) and fitted with trendlines to obtain *R* ^2^ values. Student's *t*‐tests were utilized to compare the slope and intercept (elevation) of the trendlines between autism and control groups. As we used all available tissue obtained from the respective brain banks, a power analysis was not carried out and no tests for outliers were conducted.

###### 

*B* ~max~ and *K* ~D~ for each individual ACC case in both deep and superficial layers

                                           **Anterior Cingulate Cortex**                                                                                                                                                
  ---------------------------------------- ------------------------------- -------------- --------------- ------------ ------------ ------------ -------------- -------------- -------------- ------------ ------------ --------------
  4103                                     1811                            7.50           735.3           6.78         197.6        7.24         1706           7.55           531.2          6.97         208.5        7.99
  4104                                     1205                            7.81                                        218.2        7.22         1209           7.79                                       242.6        7.63
  4267                                     2088                            7.41           211.3           7.53         306.0        6.82         2159           7.38           216.8          7.55         243.2        7.60
  4268                                     4224                            6.85           846.5           6.68         294.0        6.70         3489           6.99           778.0          6.75         181.0        7.78
  4271                                     590.2                           7.76           596.5           6.31         263.6        7.02         606.9          7.78           596.0          6.33         308.2        7.34
  4272                                     2277                            7.44           479.2           7.03         227.8        7.10         2295           7.45           805.7          6.72         265.6        7.68
  4275                                     1025                            7.85           201.8           7.24         89.2         7.85         1062           7.81           202.6          7.26         125.7        8.12
  4345                                     4241                            6.83           289.1           7.03         190.2        7.47         3242           7.05           256.8          7.13         266.7        7.92
  4364                                     2130                            7.37           166.9           7.63         163.1        7.14         2137           7.38           168.5          7.63         169.1        8.03
  4599                                     2676                            7.32           488.9           6.96         185.9        7.35         2388           7.40           484.2          6.97         235.2        7.75
  5813                                     1219                            7.76           170.2           7.17         676.3        6.62         1261           7.75           167.1          7.22         210.3        8.03
  **Mean**                                 **2135**                        **7.45**       **418.6**       **7.04**     **255.6**    **7.14**     **1960**       **7.48**       **420.7**      **7.05**     **223.3**    **7.81**
  **±SEM**                                 **364**                         **0.11**       **78.6**        **0.12**     **45.9**     **0.11**     **271**        **0.09**       **79.4**       **0.12**     **15.5**     **0.07**
  1078                                     767.8                           7.35           249.3           6.75         327.4        6.71         803.1          7.30           176.5          7.03         407.8        6.69
  1401                                     1158                            7.73           204.1           6.90         183.0        7.14         1171           7.75           201.2          6.93         355.9        7.12
  1484                                     1466                            7.66           170.0           7.39         319.4        6.95         1558           7.60           172.8          7.40         322.7        7.15
  1664                                     745.6                           7.75           202.7           6.80         304.1        7.06         764.3          7.72           272.4          6.59         339.5        7.32
  3845                                     1601                            7.48           186.9           7.72         80.1         7.83         1625           7.46           193.7          7.71         117.4        8.22
  5574                                     1474                            7.80           302.8           7.36         520.5        6.68         1567           7.80           311.4          7.39         288.2        7.41
  5754                                     1265                            7.80           274.1           7.23         630.2        6.27         1299           7.74           278.6          7.24         173.5        7.96
  5771                                     1573                            7.71           303.4           7.03         518.0        6.79         1690           7.69           318.3          7.01         289.9        7.72
  5864                                     1295                            7.47           237.6           7.41         297.1        7.11         1412           7.41           222.5          7.57         249.1        7.60
  **Mean**                                 **1261**                        **7.64**       **236.8**       **7.18**     **353.31**   **6.95**     **1321**       **7.61**       **238.6**      **7.21**     **282.7**    **7.47**
  **±SEM**                                 **107**                         **0.05**       **16.5**        **0.11**     **58.1**     **0.14**     **115**        **0.06**       **19.1**       **0.12**     **30.3**     **0.16**
  **T‐test**                               **\*0.0402**                    **0.1502**     **\*0.04752**   **0.4105**   **0.2055**   **0.2857**   **\*0.0489**   **0.2687**     **\*0.0497**   **0.3769**   **0.1068**   **\*0.0479**
  **Children**                                                                                                                                                                                                          
  3835                                     2312                            7.27           404.8           6.88         101.4        7.88         2129           7.38           364.8          6.95         155.1        7.88
  4188                                     1089                            7.73           328.8           7.32         317.0        7.06         1168           7.67           276.4          7.44         330.9        7.41
  4274                                     827.9                           8.00           186.8           7.36         288.6        7.10         852.3          7.99           173.1          7.45         275.6        7.20
  5242                                     1597                            7.51           287.9           7.28         144.7        7.51         1464           7.62           295.1          7.25         196.2        7.95
  5334                                     1760                            7.46           296.4           7.21         237.5        7.22         1585           7.54           294.9          7.23         211.7        7.86
  5376                                     2866                            6.92           374.9           7.05         315.7        7.03         2551           6.98           358.3          7.08         223.6        7.80
  5387                                     2194                            7.02           842.1           6.29         395.3        6.90         2188           7.02           732.6          6.36         257.7        7.82
  5391                                     1848                            7.55           314.5           6.81         160.4        7.68         1751           7.60           413.9          6.65         229.3        7.93
  **Mean**                                 **1812**                        **7.43**       **379.5**       **7.03**     **245.1**    **7.30**     **1711**       **7.48**       **363.6**      **7.05**     **235.0**    **7.73**
  **±SEM**                                 **233**                         **0.13**       **69.9**        **0.13**     **36.0**     **0.12**     **199**        **0.12**       **58.6**       **0.14**     **18.9**     **0.10**
  1469                                     695.3                           7.78           123.4           7.33         806.3        6.10         725.3          7.76           124.9          7.30         323.0        6.59
  2993                                     3435                            6.63           82.3            7.28         80.2         7.77         3777           6.57           85.7           7.26         93.9         8.15
  3871                                     2314                            7.37           144.0           7.32         315.5        6.69         2320           7.39           148.5          7.29         231.7        7.64
  3924                                     1344                            7.83           169.2           7.49         106.6        7.99         1399           7.81           176.2          7.48         160.2        8.20
  4334                                     2789                            7.18           662.4           6.56         334.1        6.95         2793           7.19           568.2          6.66         248.1        7.67
  4721                                     2369                            7.30           228.7           7.03         158.2        7.48         2104           7.41           224.7          7.05         193.6        7.90
  5302                                     1700                            7.72           381.9           7.18         592.3        6.60         1711           7.73           375.0          7.25         216.6        7.53
  5565                                     2035                            7.51           356.8           6.95         219.1        7.44         1965           7.54           383.7          6.89         257.7        7.63
  5841                                     1720                            7.57           183.8           7.19         145.0        7.66         1713           7.61           245.6          6.93         199.6        8.07
  **Mean**                                 **2045**                        **7.43**       **259.16**      **7.15**     **306.37**   **7.19**     **2056.4**     **7.44**       **259.17**     **7.12**     **213.82**   **7.71**
  **±SEM**                                 **269**                         **0.12**       **60.7**        **0.09**     **81.6**     **0.21**     **289**        **0.13**       **51.8**       **0.09**     **21.5**     **0.16**
  **T‐test**                               **0.5229**                      **0.9940**     **0.2140**      **0.4462**   **0.5062**   **0.6723**   **0.3423**     **0.8641**     **0.2020**     **0.6483**   **0.4701**   **0.9038**
  **T‐test all cases control vs autism**                                                                                                                                                                                
  **0.2339**                               **0.3763**                      **\*0.0174**   **0.2488**      **0.1807**   **0.3654**   **0.5145**   **0.6474**     **\*0.0162**   **0.3228**     **0.3930**   **0.1479**   

ACC, anterior cingulate cortex.

*T*‐tests were performed as described in methods to compare autism (orange) to controls (black) within groups of adults only, children only, and total cases. Asterisks mark significantly different group means.
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Results {#jnc14832-sec-0007}
=======

Each of the three cortical regions, ACC, PCC, and FG were included in all three ligands; \[^3^H\]‐ketanserin (5‐HT~2~), \[^3^H\]‐citalopram (5‐HTT), and \[^3^H\]‐8‐OH‐DPAT (5‐HT~1A~). The superficial (Lamina I--III in ACC; I--V in PCC and FG) and deep layers (Lamina V--VI) were approximately delineated from adjacent Nissl stained sections and autoradiographs as shown in Fig. [1](#jnc14832-fig-0001){ref-type="fig"}. Anatomical levels were matched as much as possible based on whole tissue blocks provided by the brain banks. The receptor distribution pattern based on the ligand binding was mostly homogeneous with \[^3^H\]‐ketanserin and \[^3^H\]‐citalopram across layers, whereas \[^3^H\]‐8‐OH‐DPAT had high binding in the superficial layers of the cortex as compared to the deep layers at most ligand concentrations, which saturated at a similar level with higher concentrations of ligand. The autism ACC case shown in Fig. [1](#jnc14832-fig-0001){ref-type="fig"} had similar binding to the control case for 5‐HT~1A~, but had lower binding for both 5‐HT~2~ and 5‐HTT indicating receptor‐specific alterations in the serotonergic system in some autism cases within the ACC.

These alterations are readily observed when comparing saturation binding curves in the ACC for control cases versus autism cases (Fig. [2](#jnc14832-fig-0002){ref-type="fig"}). There were no group differences when comparing the *B* ~max~ or *K* ~D~ of all autism and control cases for 5‐HT~1A~ and 5‐HT~2~, however, a decrease in *B* ~max~ for 5‐HTT binding was significant for the autism group (Table [3](#jnc14832-tbl-0003){ref-type="table"}). Intriguingly, when separating total control and autism cases into adults (\> 16 years) and children (≤16 years) it appears that the adult cases are mostly driving the group decrease in 5‐HTT binding. Furthermore, separating analysis of children and adults for 5‐HT~2~ binding revealed a statistically significant decrease in *B* ~max~ for adult autism cases that was not apparent when comparing the autism and control group as a whole. This indicates a similar receptor number in the ACC when comparing controls and children with autism, but a tendency for autism cases to have lower binding levels of 5‐HTT and 5‐HT~2~ than controls in adulthood.

![Individual saturation binding curves for all cases in the ACC. Individual curves each include seven concentrations of ligand. Autism (orange) cases had significantly decreased binding in both superficial and deep layers for 5‐HTT (\[^3^H\]‐citalopram) compared to control cases (black) that is driven by a lower *B* ~max~ in adult autism cases. Similarly, 5‐HT~2~ (\[^3^H\]‐ketanserin) receptor binding (*B* ~max~) was decreased in adult cases (*n* = 11 control and 9 autism), but not in children (*n* = 8 control and 9 autism). 5‐HT~1A~ \[^3^H\]‐8‐OH‐DPAT) binding was unchanged for each of the three groups; total autism and control cases, adults only and children only. *n* = individual postmortem cases. ACC, anterior cingulate cortex; 5‐HT, 5‐hydroxytryptamine (serotonin).](JNC-151-642-g002){#jnc14832-fig-0002}

While the separation of children and adults mirrors clinical studies, the cutoff age of 16 years isn't necessarily biologically relevant, as development occurs over a continuous time course. Therefore, further analyses were carried out to more clearly define the relationship between age and 5‐HT receptor expression. Plotting *B* ~max~ values against age (Fig. [3](#jnc14832-fig-0003){ref-type="fig"}) reveal similar slopes for 5‐HTT density (*p* = 0.94), but an intercept (elevation) that is significantly lower in the autism group across ages (*p* = 0.025). 5‐HT₂ density increases with age in control cases, whereas in autism there is a decrease with age and significantly different slopes between regression lines (*p* = 0.032).

![Age regression analysis. Receptor expression (*B* ~max~) plotted against age for both \[^3^H\]‐ketanserin (5‐HT~2~) and \[^3^H\]‐citalopram (5‐HTT) in the ACC. \[^3^H\]‐ketanserin had a decreasing slope in the autism group (*n* = 18) that was significantly different (*p* = 0.032) from controls (*n* = 19). \[^3^H\]‐citalopram had no difference in slope (*p* = 0.94), but had a significantly lower intercept (elevation) compared to controls (*p* = 0.025). *n* = individual postmortem cases. ACC, anterior cingulate cortex; 5‐HT, 5‐hydroxytryptamine (serotonin).](JNC-151-642-g003){#jnc14832-fig-0003}

The results from the three ligands and three cortical regions also indicate that disruptions in the serotonergic system are region specific. There were no differences in *B* ~max~ or *K* ~D~ for any ligand in the PCC or FG (see Figures [S1](#jnc14832-sup-0001){ref-type="supplementary-material"}, [S2](#jnc14832-sup-0001){ref-type="supplementary-material"}; Tables [S1](#jnc14832-sup-0001){ref-type="supplementary-material"}, [S2](#jnc14832-sup-0001){ref-type="supplementary-material"}). There were not enough female cases in the cohort to analyze differences between gender; however, the two female cases (1401 and 5771) in the adult autism group of the ACC had *B* ~max~ values that fell in the normal range of controls but higher values of the autism group, suggesting the need to analyze a larger cohort to determine if this decrease in serotonin receptors is gender specific for males.

Since some of the autism cases had a history of at least one seizure, Welch's *t*‐tests were conducted to compare the *B* ~max~ means for each ligand between autism cases with a seizure history and without. There were no statistical differences in group means in the ACC autism cases for neither \[^3^H\] ketanserin (seizure mean = 2026 ± 376.6, no seizure mean = 1520 ± 177.0, *p* = 0.26), \[^3^H\] citalopram (seizure mean = 187.3 ± 31.91, no seizure mean = 279.7 ± 34.44, *p* = 0.07) nor \[^3^H\] 8‐OH‐DPAT (seizure mean = 224.6 ± 34.53, no seizure mean = 260.1 ± 24.62, *p* = 0.42). For the two ligands showing significant differences in autism, *B* ~max~ means were not different based on source of the tissue (ATP vs. UMBTB Table [1](#jnc14832-tbl-0001){ref-type="table"}), as \[^3^H\] ketanserin *p* = 0.09 and \[^3^H\] citalopram *p* = 0.53. There was also no correlation of *B* ~max~ values to postmortem interval (Figure [S3](#jnc14832-sup-0001){ref-type="supplementary-material"}).

Although the number of autism cases with ADI‐R scores available was limited for tissue obtained from the ACC, when plotting against *B* ~max~ values (Fig. [4](#jnc14832-fig-0004){ref-type="fig"}) a significant relationship between expression and symptom severity was observed for 5‐HTT (*R* ^2 ^= 0.9839), but not for 5‐HT₂ expression (*R* ^2 ^= 0.2234).

![Symptom severity compared to receptor expression. Receptor expression (*B* ~max~) plotted against autism diagnostic interview‐revised (ADI‐R) scores (*n* = 6) with *R* ^2^ values given. Higher ADI‐R scores represent increased severity of autism symptoms. *n* = individual postmortem autism cases.](JNC-151-642-g004){#jnc14832-fig-0004}

Discussion {#jnc14832-sec-0008}
==========

Given the longstanding implications of 5‐HT dysfunction in ASD and common use of SSRIs to ameliorate adverse behaviors, it is important to determine which receptor subtypes may contribute to ASD symptoms and thus be amenable to pharmacological intervention within the central nervous system. In the present study, the ASD cohort from the PCC and FG displayed normal density and ligand affinity for 5‐HT~1A~, 5‐HT~2~, and 5‐HTT. However, in the ACC, while the 5‐HTT assay showed significant density decreases within the entire autism group (adults and children), this difference was most prominent in the adult autism cases, since the group of children mean 5‐HTT density remained unchanged. However, age regression analysis showed a consistent reduction in 5‐HTT across ages, as indicated by a lower elevation of the regression line. Whole group 5‐HT~2~ density was not altered in autism, however, when analyzing children and adults separately, the adult ACC autism cases again show significantly decreased density of 5‐HT~2~ receptors. Furthermore, 5‐HT~2~ receptor expression increased with age in controls, but decreased with age in autism. This demonstrates age‐dependent differences in 5‐HT within the ACC in a subset of ASD individuals. These findings are particularly intriguing in light of the clinical efficacy of SSRI use. SSRI drugs are commonly administered to individuals with autism, as up to 80% of children with ASD experience clinically significant anxiety (Muris *et al.* [1998](#jnc14832-bib-0046){ref-type="ref"}; Leyfer *et al.* [2006](#jnc14832-bib-0039){ref-type="ref"}; Simonoff *et al.* [2008](#jnc14832-bib-0068){ref-type="ref"}). Nadeau *et al.*([2011](#jnc14832-bib-0048){ref-type="ref"}) concluded, in a review of treatment studies, that cognitive‐behavior therapies may be more helpful than SSRI administration in youth with ASD. As reaffirmed in the 2013 Cochrane Review (Williams *et al.* [2013](#jnc14832-bib-0076){ref-type="ref"}), there is no conclusive evidence that children benefit from SSRIs, but have been shown in major clinical trials to have significant adverse outcomes (e.g. King *et al.* [2009](#jnc14832-bib-0033){ref-type="ref"}) in contrast to some adults with autism that do benefit from SSRIs. Our data parallels this information in that only a subset of adults with autism (\> 16 years of age) have decreased density of 5‐HT~2~ and 5‐HTT in the ACC, but children appear to have normal levels in all three cortical regions evaluated. It remains to be explored whether there are similar 5‐HT receptor deficits in other brain regions in autism or whether the ACC is a more susceptible area than other cortical brain regions.

A possible explanation for inconsistent results within the literature regarding the 5‐HT system in ASD is the heterogeneity inherent to the condition amidst small sample sizes. For example, genetic polymorphisms in the 5‐HT transporter have been implicated in ASD (Yonan *et al.* [2003](#jnc14832-bib-0077){ref-type="ref"}; Devlin *et al.* [2005](#jnc14832-bib-0018){ref-type="ref"}; Sutcliffe *et al.* [2005](#jnc14832-bib-0069){ref-type="ref"}; Kistner‐Griffin *et al.* [2011](#jnc14832-bib-0034){ref-type="ref"}; Najjar *et al.* [2015](#jnc14832-bib-0049){ref-type="ref"}), however, it is only a subset of individuals, presuming the majority of ASD cases do not show genetic differences in 5‐HTT. Furthermore, most imaging studies involving ASD, as discussed in the introduction, focus on high‐functioning individuals that may not be representative of the entire autism spectrum. The data presented here show mean decreases in receptor density in superficial and deep layers of the ACC in the adult autism groups, but several autism cases fall within the normal control range, indicating that not every autism case shows differences in specific 5‐HT receptor subtypes in the examined areas. Furthermore, while hyperserotonemia is considered the best replicated biomarker in autism, it still represents less than half of the ASD population (Gabriele *et al.* [2014](#jnc14832-bib-0021){ref-type="ref"}). For these reasons, treatments for ASD should be tailored to the individual. As tests for peripheral hyperserotonemia and genetic variants become more widely available, future studies evaluating the efficacy of SSRIs in autism should divide individuals into subgroups based on evidence of 5‐HT disruption. As demonstrated by the data presented and by clinical SSRI outcomes, age of the individual may be a key factor for positive clinical outcomes, however, not all studies divide cohorts by age. For example, in a 6‐week open label trial with 44 participants with autism, two increasing daily doses of the SSRI escitalopram resulted in improvement on insistance of sameness and irritability symptoms irrespective of whether individuals had polymorphisms of 5‐HTT (SLC6A4) or of the 5‐HT2A receptor (HTR2A). However, differences in age groups were not reported despite subjects in the study falling between 5 and 44 years old (Najjar *et al.* [2015](#jnc14832-bib-0049){ref-type="ref"}). Interestingly, symptom severity was correlated with 5‐HTT expression, but not with 5‐HT~2~ receptor expression. Higher ADI‐R scores represent increased symptom severity, which was correlated with higher 5‐HTT expression in a subset of autism cases in which ADI‐R scores were available. It is not clear why higher expression would be correlated with symptom severity, as control cases have higher expression. However, the expression of 5‐HTT is dependent on a diverse set of mechanisms (Daws and Gould [2011](#jnc14832-bib-0015){ref-type="ref"}). As 5‐HTT is the uptake site of 5‐HT, its regulation is dependent on 5‐HT expression. If there is an increase in brain serotonin (central hyperserotonemia), a downregulation of 5‐HTT would help to offset its effects and if individuals were unable to downregulate 5‐HTT (due to a polymorphism or other reason), that heightened 5‐HT within the brain could be associated with more severe autistic symptoms. Further research is needed to clarify the development of the serotonergic system in autism, particularly in how receptors respond to altered levels of 5‐HT during development of the brain. The results of the present study also suggest that 5‐HT dysfunction may be secondary to other mechanisms or emerge as a compensation pattern within disrupted circuits. As suggested by our data, if the 5‐HTT reductions begin in childhood, it is possible that the reductions in 5‐HT~2~ in adults are occuring in response to this initial deficit. Further studies that evaluate changes in 5‐HT in ASD with age will be needed to determine whether children that have normal levels of 5‐HT receptors at a young age present with deficits later in life or whether these individuals had 5‐HT alterations throughout development. Since there were no differences in ligand binding affinity across each cortical region and ligand, it is unlikely our cohort had significant genetic risk in relationship to 5‐HT~1A,~ 5‐HT~2~, or 5‐HTT, which would again indicate a compensation pattern of 5‐HT alterations instead of a primary 5‐HT causative factor.

As individuals with ASD are commonly prescribed SSRIs at a young age, the need for informed use of pharmacological interventions is warranted. Our data adds to the growing literature that caution should be taken toward SSRIs in children under the age of 16 and that the 5‐HT system can be altered within distinct cortical regions and receptor subtypes.

The ACC has consistent neurochemical, cytoarchitectural, and connectivity differences in adults with idiopathic autism {#jnc14832-sec-0009}
----------------------------------------------------------------------------------------------------------------------

An intriguing result of the present study is the selective vulnerability of the ACC versus the PCC or FG due to changes in binding of 5‐HT~2~ receptors and 5‐HTT only in the ACC. Previous studies identified cytoarchitectual changes, including increased packing density, in ACC subregions and increased neurons in the white matter just below layer VI in about half of the adult autism postmortem cases in the study (Simms *et al.* [2009](#jnc14832-bib-0067){ref-type="ref"}). A multimodal imaging study found that the ACC cytoarchitectural changes related to symptom severity in individuals with neurodevelopmental conditions including autism (Forde *et al.* [2018](#jnc14832-bib-0020){ref-type="ref"}). In a recent landmark postmortem study of ACC connectivity, Zikopoulos *et al.*([2018](#jnc14832-bib-0078){ref-type="ref"}) demonstrated an increased proportion of thin axons in the white matter just below the ACC from childhood through adulthood, which was indicative of hyper‐connectivity to short range neighboring cortices and a decreased proportion of thick diameter axons below the ACC, representing hypo‐connectivity of long range cortical connectivity.

Neurochemical differences in the autism ACC have been reported by Oblak *et al.*([2009](#jnc14832-bib-0052){ref-type="ref"}, [2010](#jnc14832-bib-0053){ref-type="ref"}). These authors reported significant decreases in GABA‐ARs and GABA‐BRs in the ACC in adult postmortem autism cases in superficial (I--III) and deep layers (V--VI). A recent proton magnetic resonance spectroscopic study by Ito *et al.*([2017](#jnc14832-bib-0029){ref-type="ref"}) reported hypoGABAergic alterations in children with autism, but normal glutamate markers suggesting that the ACC may contribute to excitatory/inhibitory imbalance in subjects with idiopathic autism.

Using cognitive measures, behavioral analysis, and functional magnetic resonance imaging tasks in adults with idiopathic autism, Balsters *et al.*([2017](#jnc14832-bib-0005){ref-type="ref"}) concluded that the ACC is a critical component of social behavior and that socially‐specific prediction errors occurred in the autism group. These authors also concluded that connectivity between the ventral medial prefrontal cortex and the ACC may represent a neural substrate underlying the social deficits. In fact, ACC activity can be monitored via 5‐HT~2~ receptors in rat pups as early as P10‐P12 and is modulated by maternal contact, which increases local field potentials in low frequency bands (Courtiol *et al.* [2018](#jnc14832-bib-0014){ref-type="ref"}).

Collectively, these and other studies demonstrate that the ACC is a critical node for a variety of high‐order functions in the neurotypical brain. In autism, there are both structural changes in cortical lamination in the ACC in early development and through adulthood, as well as neurochemical changes in critical neurotransmitter systems, which includes GABA and serotonin as demonstrated by significant alterations in receptor densities across superficial‐deep lamina. This suggests that modulation of both input and output of the principal pyramidal neurons of the ACC may be impacted, potentially resulting in altered short and long‐range connectivity differences and affecting a wide range of autism‐related behaviors.

Summary and conclusions {#jnc14832-sec-0010}
=======================

Some SSRIs administered to individuals with autism reported successful treatment of various symptoms, but citalopram hydrobromide had variable results that included harmful effects when administered to children. Previous studies have reported more favorable results when citalopram was administered to autistic individuals with specific polymorphisms. SSRIs mainly target the serotonin transporter and its blocking action allows 5‐HT to persist at the synapse. SSRIs are drugs that typically also affect other 5‐HT receptors, as well as dopamine and other receptor types. Multiple concentration ligand binding autoradiography is still a very useful tool to quantify the number (*B* ~max~) and affinity (*K* ~D~) of a variety of receptor types and was applied to this study investigating whether 5‐HTT and other major subtypes of 5‐HT receptors (5‐HT~2~ and 5‐HT~1A~) had significant changes in children and/or adult autism cohorts as compared to neurotypically developing individuals. Receptor density (*B* ~max~) changes were seen in ^3^\[H\]‐citalopram labeled 5‐HTT and in ^3^\[H\]‐ketanserin labeled 5‐HT~2~ receptors in the adult autism group in the ACC only, but not in children. Furthermore, there were no changes in ^3^\[H\]‐8‐OH‐DPAT labeled 5‐HT~1A~ receptors in any of the groups or cortices. This study therefore provides further evidence that the ACC is a highly vulnerable region in autism, with changes in a number of receptor types that may contribute to the excitatory/inhibitory imbalance in the autism brain via disruptions in its cytoarchitecture and connectivity with other local and distant cortices. This could potentially have profound effects within cortical networks that, in part, underlie autism‐related behaviors.
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**Figure S1**. Individual saturation binding curves for all cases in the PCC.

**Figure S2**. Individual saturation binding curves for all cases in the FG.

**Figure S3**. Postmortem interval (PMI) versus receptor binding.

**Table S1**. *B* ~max~ and *K* ~D~ for each individual PCC case in both deep and superficial layers.

**Table S2**. *B* ~max~ and *K* ~D~ for each individual FG case in both deep and superficial layers.
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